Share on StockTwits

Shares of LeMaitre Vascular (NASDAQ:LMAT) have earned a consensus recommendation of “Buy” from the nine brokerages that are covering the stock, Stock Ratings Network.com reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $10.54.

LeMaitre Vascular (NASDAQ:LMAT) traded up 8.68% on Tuesday, hitting $7.76. The stock had a trading volume of 18,960 shares. LeMaitre Vascular has a 52-week low of $6.38 and a 52-week high of $8.96. The stock’s 50-day moving average is $7.6 and its 200-day moving average is $7.90. The company has a market cap of $121.3 million and a P/E ratio of 51.37.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings data on Tuesday, April 29th. The company reported $0.01 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.02 by $0.01. On average, analysts predict that LeMaitre Vascular will post $0.23 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on LMAT shares. Analysts at Stifel Nicolaus initiated coverage on shares of LeMaitre Vascular in a research note on Tuesday. They set a “buy” rating and a $11.00 price target on the stock. Separately, analysts at Stifel initiated coverage on shares of LeMaitre Vascular in a research note on Tuesday. They set a “buy” rating and a $11.00 price target on the stock. Finally, analysts at Brean Capital initiated coverage on shares of LeMaitre Vascular in a research note on Monday, May 19th. They set a “buy” rating and a $11.00 price target on the stock.

LeMaitre Vascular, Inc (NASDAQ:LMAT) is a global provider of medical devices and implants for the treatment of peripheral vascular disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.